Delving into the Latest Updates on Paragon Biomedical, Inc. with Synapse

A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy

The purpose of this study is to examine the impact of intradermal delivery of NP2 on pain scores and pain medication usage in subjects with intractable pain due to malignant disease. A second purpose is to confirm safety and secondary efficacy measurements.

开始日期2011-01-01

申办/合作机构

Diamyd, Inc.

[+2]

NCT00710580

/ Completed临床3期

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis

开始日期2008-07-01

申办/合作机构

AbbVie, Inc.

[+1]

NCT00691964

/ Completed临床3期

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis

开始日期2008-05-01

申办/合作机构

AbbVie, Inc.

[+1]

100 项与 Paragon Biomedical, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Paragon Biomedical, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Paragon Biomedical, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Paragon Biomedical, Inc. 相关的转化医学